Racial/Ethnic Disparities in Infant Mortality -United States, 1995-2002
A national health objective for the year 2000 was to reduce the infant mortality rate (IMR) in the United States to 7.0 deaths per 1,000 live births among infants aged <1 year (1, 2) . The national health objective for 2010 targets a rate of 4.5 infant deaths per 1,000 live births (3); an overarching goal calls for eliminating disparities among racial and ethnic populations. To examine racial and ethnic disparities in IMRs, data were analyzed from the National Vital Statistics System for the period 1995-2002. IMRs were calculated by race/ethnicity of the mother in each of the 50 states and the District of Columbia (DC). During 1995-2002, the overall IMR in the United States declined from 7.6 infant deaths per 1,000 live births in 1995 to 6.8 in 2001, and then increased to 7.0 in 2002 ( Figure) (4) (5) (6) . On the basis of data for 1995-2002 combined, the target of 4.5 infant deaths per 1,000 live births had been achieved by few racial/ethnic populations in few states. To reach the target in all racial/ethnic populations, strategies should identify and address those factors that contribute to high IMRs and disparities among populations.
Data for this report were obtained from the linked birth/ infant death data sets for 1995-2002 maintained by CDC's National Center for Health Statistics. These data sets link birth and death certificate information registered in all 50 states and DC for infants aged <1 year who died in the United States (4) . Rates by race and Hispanic origin of the mother were calculated by using the linked data sets because race and ethnicity information about the mother from the birth certificate is more accurate than information about the infant from the death certificate (6) . Annual data for [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] were combined to maximize the number of events and statistical reliability of rates for racial/ethnic populations in the 50 states and DC.
During 1995-2002, IMRs declined for all racial/ethnic populations; however, the decrease for infants of American Indian/Alaska Native mothers was not statistically significant. 
Travel-Associated Dengue InfectionsUnited States, 2001-2004
Dengue is a mosquito-transmitted, acute viral disease caused by any of the four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Dengue is endemic in most tropical and subtropical areas of the world and has occurred in U.S. residents returning from travel to such areas (1-3). CDC maintains a laboratory-based passive surveillance system for travel-associated dengue among U.S. residents*. The system relies on voluntary reports submitted to state health departments by clinicians; patient specimens are then forwarded to CDC for diagnostic testing. This report summarizes information about travel-associated dengue cases among U.S. (Table) . Of the 77 acute infections, eight (10%) were diagnosed as primary infections, and 12 (16%) were secondary infections. For the remaining 57 cases (74%), whether the infection was the patient's first dengue infection or a subsequent infection could not be determined either because a convalescent sample (collected more than 5 days after symptom onset) was not submitted, or both samples were collected during the convalescent phase of infection. Among the 366 suspect cases, dengue testing was negative in 183 patients (50%). A total of 22 patients (6%) had elevated IgG titers, suggesting that a flavivirus infection or vaccination (e.g., yellow fever) had occurred in the past but that infection was not the cause of the acute symptoms. For 88 patients (24%), the result of dengue testing was indeterminate because a convalescent sample for serologic testing was unavailable.
Of the 77 patients with laboratory-diagnosed dengue infections, 41 (53%) were female. The median age of the 71 patients for whom age was reported was 38 years (range: 8 months-72 years). Clinical information was available for 56 patients (73% 36%] ). Fourteen patients (25%) had at least one hemorrhagic symptom (e.g., petechiae, purpura, hemoptysis, hematemesis, hematuria, or epistaxis), and nine (16%) had elevated liver transaminases. Because of incomplete reporting, whether any of the laboratory-diagnosed cases met the clinical criteria for dengue hemorrhagic fever (DHF) could not be determined; however, 15 patients (27%) required hospitalization, including one who died. The fatal case occurred in an adult in otherwise good health who had recently returned from a month-long visit to Mexico. Travel destinations were available for 66 patients (86%); 20 patients (30%) reported recent travel to a Caribbean island during the 2 weeks before illness onset, 14 (21%) to Pacific islands, 11 (17%) to Asia, 10 (15%) to (6) . The incubation period for dengue has a range of 3-14 days (in the majority of cases, 4-7 days). Dengue virus infection can be asymptomatic or cause illnesses ranging from mild undifferentiated fever to severe disease, including hemorrhagic manifestations and shock (7) . DHF is characterized by fever, minor or major bleeding phenomena, thrombocytopenia (<100,000 platelets/µL), and evidence of increased vascular permeability (e.g., hemoconcentration [hematocrit increased by >20% from baseline], pleural or abdominal effusions, or hypoproteinemia) (7) . Previous dengue infection increases the risk for DHF in a patient with subsequent dengue infection. Dengue shock syndrome is DHF with signs of circulatory failure, including narrow pulse pressure (<20 mm Hg), hypotension, or shock, and can result in a case-fatality rate of approximately 10% (8) .
The findings in this report are subject to at least one limitation. These data are likely subject to underreporting because 1) the system is passive (i.e., relies on providers to report infection), 2) dengue reporting is not a nationally notifiable disease in the United States, and 3) reporting is tied to specimen submission (i.e., if testing is completed outside of CDC, this system would not capture the results).
Persons traveling to areas in which dengue is endemic should avoid exposure to mosquitoes by using repellents, wearing protective clothing, and remaining in well-screened or air-conditioned areas. No vaccine is available for preventing dengue infection. Health-care providers should consider dengue in the differential diagnoses of illness for all patients who have fever and a history of travel to tropical and subtropical areas within 2 weeks before the onset of symptoms. Supportive measures should be administered, and only acetaminophen is recommended for management of pain and fever. Acetylsalicylic acid (i.e., aspirin) and other nonsteroidal antiinflammatory agents are contraindicated because of their anticoagulant properties and, in the case of children, because of their association with Reye Syndrome. Patients with dengue should be monitored for signs of DHF, especially hypotension, because prompt fluid therapy reduces morbidity and mortality.
Acute-phase (0-5 days after onset of symptoms) and convalescent-phase (6-30 days after onset of symptoms) serum samples obtained for viral isolation and serologic diagnosis, respectively, should be sent through state or territorial health departments to CDC's Dengue Branch, Division of VectorBorne Infectious Diseases, National Center for Infectious Diseases, 1324 Calle Cañada, San Juan, PR 00920-3860, telephone 787-706-2399, fax 787-706-2496. Serum samples should be accompanied by a summary of clinical and epidemiologic information, including date of disease onset, date of sample collection, and a detailed recent travel history. Additional information for health-care providers regarding dengue case reporting and instructions for specimen shipping are available at http://www.cdc.gov/ncidod/dvbid/dengue/ dengue-hcp.htm.
Reporting of Chlamydial InfectionMassachusetts, January-June 2003
Chlamydia trachomatis infection is the most commonly reported sexually transmitted disease (STD) in the United States. An estimated 2.8 million infections occur annually (1) . In 2002, a total of 834,555 cases in the United States, including 10,914 cases in Massachusetts, were reported through the National Notifiable Disease Surveillance System (NNDSS) (2) . Chlamydial infection is most often reported in females, particularly those aged 15-24 years, reflecting a higher level of screening in females (3) but also important risk factors*. Although the majority of infections are asymptomatic, complications are potentially severe in women and include pelvic inflammatory disease, which can lead to tubal pregnancy, infertility, and chronic pelvic pain (3) . Chlamydial infection during pregnancy can cause illness in the infant (e.g., conjunctivitis and pneumonia). Infection in men can manifest as urethritis and epididymitis. Timely, documented diagnosis and treatment of chlamydial infection are critical to prevent both complications and transmission. Since 1996, a progressive increase has occurred in the number of reported cases of chlamydial infection in Massachusetts (Figure 1 ), in part because of an increase in screening and use of more sensitive tests. This report summarizes an evaluation of chlamydialinfection reporting in Massachusetts during January-June 2003. The results underscore the need for improvement in both completeness and timeliness of reporting chlamydial infection in Massachusetts.
Massachusetts law requires all laboratories (both in-state and out-of-state) and health-care providers (HCPs) to report within 24 hours evidence of chlamydial infection in any state resident (including college students from out of state). These data are used to assess contact follow-up and identify outbreaks. All cases are defined by laboratory diagnosis (e.g., isolation of C. trachomatis by culture, or detection of antigen or nucleic acid). Reports from both laboratories and HCPs are entered into STD*MIS, a database developed by CDC for use by state health departments.
During January-June 2003, four laboratories in the state submitted their reports electronically to the Massachusetts Department of Public Health (MDPH). Certain laboratories reported daily by fax, mail, or electronically; others submitted their reports weekly or monthly, despite the requirement for 24-hour reporting. Laboratory reports do not contain information about indication for the test or treatment received. HCPs report to MDPH by using case-report cards, which include demographic, diagnosis, and treatment data.
A morbidity record is created in STD*MIS by using data from whichever report (i.e., laboratory or HCP) is received first; the record is supplemented with data from whichever report is received second. Elimination of duplicate records is addressed through a combination of 1) systematic assessment of all laboratory reports and all HCP case reports for selected demographic indicators (i.e., patient name, address, and date of birth) as data are entered and 2) periodic (i.e., every 1-3 months) review of the database for duplicate records. Multiple records for the same person are considered to represent the same case of illness if the recorded dates of onset or diagnosis are within 14 days of each other (and considered as separate cases if those dates are >14 days apart).
A disease-intervention specialist is assigned to follow up on a case-report card that indicates no evidence of treatment (even if no matching laboratory report exists). Because of resource limitations, positive laboratory reports without matching HCP case-report cards receive no follow-up from MDPH.
Data reported during January-June 2003 from 48 laboratories and 510 HCPs in Massachusetts were evaluated for completeness and timeliness. Completeness of reporting was calculated by using the Sekar-Deming capture-recapture method (5), which compares data from two sources and estimates the number of cases missed by both sources and the estimated total number of cases. Timeliness of reporting chlamydial infection was determined by calculating the median number of days from laboratory specimen collection (for cases reported by HCPs) or date of positive laboratory test (for cases reported by laboratories) to date of reporting to MDPH for all reports submitted during January-June 2003.
Capture-recapture calculations indicated that an estimated 1,757 cases of chlamydial infection were not reported to MDPH by either laboratories or HCPs during January-June 2003 and that the estimated total number of cases that occurred during that period was 7,016 ( Figure 2 ). Using these values, the completeness of reporting was estimated at 46% for laboratory reports alone and 54% for HCP reports alone; 25% of cases were reported by both laboratories and HCPs. Using either laboratory and/or HCP reporting, the system accounted for 75% of the estimated total number of cases. In addition, of the 5,259 discrete cases reported to MDPH, 1,493 (28%) were reported only by laboratories and, therefore, did not receive case follow-up.
Calculations of timeliness determined that median reporting times were 8 days for laboratories (interquartile range [IQR]: 6-13 days) and 12 days for HCPs (IQR: 8-20 days). Timeliness of electronic reporting versus paper-based reporting was not assessed in this study. Editorial Note: The findings in this report identify the need to improve reporting of chlamydial infections in Massachusetts. Laboratories and HCPs are not reporting all of their cases, 28% of reported cases do not receive follow-up, and reporting is likely not timely enough to allow for intervention and to prevent transmission. Delayed reporting has a potential negative impact on the abilities of health departments to identify changes in disease trends and to conduct contact follow-up. Studies have demonstrated poor completeness of STD reporting and even worse timeliness among paper-based reporting systems (6) . Electronic reporting by laboratories is more timely and complete than paper-based reporting and results in greater numbers of laboratory-based reports (7) .
Although laboratory reporting is considered more timely and complete, HCP reporting is still required by many states. A recent informal survey conducted by MDPH of the National Coalition of STD Directors of 16 project areas revealed that all areas required HCPs to report cases, most systems were paper-based, and response time required for both laboratories and HCPs differed by area (i.e., ranging from immediate to 7 days; one area had no time requirement) (MDPH, unpublished data, 2005). Although most project areas had not conducted formal evaluations of their surveillance systems, one of the 16 areas presently uses electronic reporting, and three of the 16 responding project areas are converting to Internet-based reporting. HCP reporting is still regarded as important because clinical data are generally absent from laboratory reports. As the electronic medical record becomes more common, linking laboratory reports to HCP electronic health records might become more feasible.
The findings in this report are subject to at least one limitation. The capture-recapture method requires that the two systems being evaluated are independent, the study population is stable, and the events captured (e.g., diagnoses of chlamydial infection) are confirmed positives (8) . Although HCPs are required to report presumptive cases of chlamydial infection, HCP reports were typically generated only after laboratory confirmation. This interaction might potentially increase the number of cases reported by both sources and the sensitivity of reporting from both sources. Therefore, the values obtained are likely overestimated.
Multiple elements of the Massachusetts reporting system could be improved. For example, certain laboratories were unaware of the requirement to report chlamydial infections. As laboratories are identified through review of submitted HCP case reports, each laboratory might be contacted to ensure awareness of the requirement and that reports are submitted promptly. In addition, periodic surveys of HCPs might be conducted to identify which laboratories they use for diagnosis of chlamydial infection, with subsequent contact of those laboratories to ensure they are reporting.
Public health surveillance systems should be evaluated periodically to ensure that problems of public health importance are being monitored efficiently and effectively (9) . This recommendation from CDC (10) has been integrated into the core components and strategies being developed by the STD Division at MDPH. The requirement for laboratories to report a positive result within 24 hours will be maintained. As of June 7, 2005, a total of 10 laboratories in Massachusetts reported electronically, which should improve completeness and timeliness, key elements of the STD surveillance system that MDPH will continue to periodically evaluate. Nursing assistants are frontline caregivers in nursing homes, responsible for assisting residents with their activities of daily living, such as dressing, bathing, and eating. From 1985 to 1999, the number of nursing home assistant full-time equivalents per 100 residents increased 14%. The increase in nursing assistants nationwide corresponds with increases in the number of residents needing assistance. During the same period, the proportion of nursing home residents requiring assistance to dress increased from 79% to 87%. Errata: Vol. 54, Nos. 12-20
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